{"nctId":"NCT02547441","briefTitle":"Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle","startDateStruct":{"date":"2015-12","type":"ACTUAL"},"conditions":["Rosacea"],"count":463,"armGroups":[{"label":"Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: CLS001 (Omiganan)"]},{"label":"Vehicle Gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]}],"interventions":[{"name":"CLS001 (Omiganan)","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Healthy, male and non-pregnant female subjects, 18 years of age or older.\n2. A diagnosis of papulopustular rosacea with â‰¥30 inflammatory facial lesions at Baseline. Subjects must have no more than 2 nodular lesions, at Baseline.\n3. Subjects with the presence of telangiectasia at Baseline.\n4. Subjects with an erythema score of at least 2 on the Investigator Assessment of Erythema scale at Baseline.\n5. Subjects with severe rosacea on the Investigators Global Assessment scale at Baseline.\n\nExclusion Criteria:\n\n1. Subjects with steroid rosacea or subtype 3 (phymatous rosacea).\n2. Subjects with nodular rosacea.\n3. Standard exclusion criteria.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Inflammatory Lesion Count From Baseline to Week 12","description":"Change from Baseline to Week 12 in Inflammatory Lesion Count","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.1","spread":"1.77"},{"groupId":"OG001","value":"-13.5","spread":"1.85"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Achieved 2 Grade IGA Reduction.","description":"Percentage of participants who achieved 2 grade IGA reduction at Week 12. IGA scores are from 0 to 5 (Clear, Almost Clear, Mild, Moderate and Severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"16.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Number of Inflammatory Lesions From Baseline at Week 9","description":"The absolute change in inflammatory lesions from baseline to Week 9","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.4","spread":"1.55"},{"groupId":"OG001","value":"-15.2","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Change in the Number of Inflammatory Lesions From Baseline at Week 6","description":"The absolute change in inflammatory lesions from baseline to Week 6","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":"1.44"},{"groupId":"OG001","value":"-11.8","spread":"1.48"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved 2 Grade IGA Reduction at Week 9.","description":"Percentage of participants who achieved 2 grade IGA reduction at Week 9. IGA scores are from 0 to 5 (Clear, Almost Clear, Mild, Moderate and Severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"14.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved 2 Grade IGA Reduction at Week 6.","description":"Percentage of participants who achieved 2 grade IGA reduction at Week 6. IGA scores are from 0 to 5 (Clear, Almost Clear, Mild, Moderate and Severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":235},"commonTop":["Viral upper respiratory tract infection","Headache","Upper respiratory tract infection","Rosacea","Application site pain"]}}}